See more : Orosil Smiths India Limited (OROSMITHS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Lasa Supergenerics Limited (LASA.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lasa Supergenerics Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- World Poker Fund Holdings, Inc. (WPFH) Income Statement Analysis – Financial Results
- Schindler Holding AG (SCHP.SW) Income Statement Analysis – Financial Results
- Nanya Technology Corporation (2408.TW) Income Statement Analysis – Financial Results
- Digital World Acquisition Corp. (DWAC) Income Statement Analysis – Financial Results
- ChromoGenics AB (CHRO.ST) Income Statement Analysis – Financial Results
Lasa Supergenerics Limited (LASA.BO)
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use comprising potassium iodide. It also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04B | 1.30B | 1.37B | 2.02B | 1.67B | 1.70B | 2.44B | 1.99B | 0.00 |
| Cost of Revenue | 756.40M | 1.10B | 943.43M | 1.14B | 955.14M | 1.29B | 1.73B | 1.34B | 0.00 |
| Gross Profit | 286.95M | 192.97M | 427.84M | 886.86M | 717.43M | 406.52M | 706.58M | 651.75M | 0.00 |
| Gross Profit Ratio | 27.50% | 14.89% | 31.20% | 43.82% | 42.89% | 23.97% | 29.01% | 32.79% | 0.00% |
| Research & Development | 1.32M | 1.02M | 2.02M | 3.74M | 3.38M | 1.64M | 2.15M | 1.70M | 0.00 |
| General & Administrative | 32.16M | 35.71M | 50.99M | 39.96M | 19.46M | 19.05M | 18.27M | 13.39M | 0.00 |
| Selling & Marketing | 9.25M | 20.98M | 20.12M | 29.69M | 31.16M | 9.84M | 9.60M | 1.93M | 0.00 |
| SG&A | 41.41M | 56.68M | 71.11M | 69.65M | 50.62M | 28.89M | 27.87M | 15.32M | 0.00 |
| Other Expenses | 245.55M | 8.63M | 128.00K | 87.00K | 2.32M | 3.18M | -1.29M | -242.00K | 0.00 |
| Operating Expenses | 286.95M | 373.96M | 404.59M | 572.45M | 561.60M | 481.84M | 475.45M | 270.75M | 0.00 |
| Cost & Expenses | 1.04B | 1.48B | 1.35B | 1.71B | 1.52B | 1.77B | 2.20B | 1.61B | 0.00 |
| Interest Income | 419.00K | 310.00K | 838.00K | 490.00K | 2.32M | 1.57M | 34.14M | 21.74M | 0.00 |
| Interest Expense | 19.74M | 41.57M | 245.00K | 16.76M | 72.96M | 71.51M | 94.53M | 109.62M | 0.00 |
| Depreciation & Amortization | 106.73M | 134.19M | 145.11M | 158.24M | 173.39M | 193.09M | 181.67M | 76.88M | 0.00 |
| EBITDA | -65.08M | -246.86M | 84.12M | 472.65M | 301.79M | 113.52M | 412.79M | 457.32M | 0.00 |
| EBITDA Ratio | -6.24% | -4.22% | 11.79% | 23.25% | 19.17% | 6.21% | 17.60% | 23.68% | 0.00% |
| Operating Income | -84.31M | -181.28M | 23.23M | 317.01M | 155.75M | -79.61M | 231.08M | 381.01M | 0.00 |
| Operating Income Ratio | -8.08% | -13.99% | 1.69% | 15.66% | 9.31% | -4.69% | 9.49% | 19.17% | 0.00% |
| Total Other Income/Expenses | -106.81M | -422.65M | -61.55M | -417.01M | -108.38M | -81.42M | -78.75M | -359.58M | 0.00 |
| Income Before Tax | -191.13M | -422.65M | -61.39M | 294.91M | 47.36M | -161.03M | 152.33M | 21.43M | 0.00 |
| Income Before Tax Ratio | -18.32% | -32.62% | -4.48% | 14.57% | 2.83% | -9.50% | 6.26% | 1.08% | 0.00% |
| Income Tax Expense | 26.18M | -36.44M | -8.08M | 67.14M | 11.08M | -40.72M | 28.93M | -2.20M | 0.00 |
| Net Income | -217.31M | -386.21M | -53.31M | 227.78M | 36.28M | -120.31M | 123.40M | 23.62M | 0.00 |
| Net Income Ratio | -20.83% | -29.81% | -3.89% | 11.25% | 2.17% | -7.09% | 5.07% | 1.19% | 0.00% |
| EPS | -4.34 | -7.71 | -1.06 | 5.60 | 0.89 | -5.26 | 5.43 | 1.15 | 0.00 |
| EPS Diluted | -4.34 | -7.71 | -1.06 | 5.60 | 0.89 | -5.26 | 5.43 | 1.15 | 0.00 |
| Weighted Avg Shares Out | 50.07M | 50.10M | 50.10M | 40.67M | 40.67M | 22.86M | 22.73M | 20.63M | 22.84M |
| Weighted Avg Shares Out (Dil) | 50.10M | 50.10M | 50.10M | 40.67M | 40.67M | 22.86M | 22.73M | 20.63M | 22.84M |
Source: https://incomestatements.info
Category: Stock Reports